ArticleMolecular biology reports2026
Harnessing Lactiplantibacillus plantarum as an anti-fungal candidate against drug resistant Candida albicans.
Article in Molecular biology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCandida albicans is a human opportunistic pathogen responsible for superficial and invasive candidiasis. It is one of the emerging nosocomial pathogens infecting immunocompromised and debilitated individuals, increasing the rate of secondary infections in diseases like HIV. The emerging drug resistance among species is making treatment cumbersome. Also, biofilm-forming ability of C. albicans is one of the primary factors contributing to its virulence as its blocks the penetration of drugs, therefore leading to drug inefficacy. Lactiplantibacillus plantarum, a part of the normal flora known for its antimicrobial properties against pathogens. METHODS AND
resultsLactobacillus FL5 was isolated from fermented milk sample and identified as Lactiplantibacillus plantarum. The culture supernatant (CS) of FL5 showed 21 mm zone of inhibition against C. albicans MTCC 4748 using agar-well diffusion assay. Lact. plantarum FL5 showed 75.8% co-aggregation with C. albicans at 8 h using spectroscopic technique. Both antibiofilm and dispersal potential of CS of FL5 against C. albicans biofilms were evaluated using crystal violet assay and images were recorded using field emission scanning electron microscopy (FESEM). FL5 showed 77% biofilm inhibition and 37% dispersal of preformed C. albicans biofilms. The production of organic acids, phenolics, aldehydes and ketones in CS was estimated using high performance liquid chromatography (HPLC) and fourier transform infrared spectroscopy (FTIR). The gas chromatography- flame ionization detection (GC-FID) showed presence of 0.8 ppm butyric acid, followed by acetic acid (0.143 ppm) and propionic acid (0.115 ppm) in CS.
conclusionThe use of Lact. plantarum as a potential candidate for targeting C. albicans biofilms to tackle antimicrobial resistance and effective treatment.
Indexed as
Identifiers
41886170What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.